Skip to main content
Top
Published in: BMC Infectious Diseases 1/2011

Open Access 01-12-2011 | Research article

Antibody dynamics and spontaneous viral clearance in patients with acute hepatitis C infection in Rio de Janeiro, Brazil

Authors: Alexander M Strasak, Arthur Y Kim, Georg M Lauer, Paulo S de Sousa, Cleber F Ginuino, Carlos A Fernandes, Carlos E Velloso, Adilson J de Almeida, Jaqueline M de Oliveira, Clara F Yoshida, Julian Schulze zur Wiesch, Gláucia Paranhos-Baccalá, Stefan Lang, Larry J Brant, Hanno Ulmer, Susanne Strohmaier, Lalit Kaltenbach, Elisabeth Lampe, Lia L Lewis-Ximenez

Published in: BMC Infectious Diseases | Issue 1/2011

Login to get access

Abstract

Background

The anti-HCV antibody response has not been well characterized during the early phase of HCV infection and little is known about its relationship to the clinical course during this period.

Methods

We analyzed serial anti-HCV antibodies longitudinally obtained from a prospective cohort of 65 patients with acute HCV infection by using a microparticle enzyme immunoassay AxSYM HCV 3.0 (Abbott Diagnostics) during the first 12 months from HCV acquisition in Rio de Janeiro, Brazil. Spontaneous viral clearance (SVC) was defined as undetectable HCV RNA in serum, in the absence of treatment, for three consecutive HCV PCR tests within 12-months of follow-up.

Results

Baseline antibody values were similar among patient groups with self-limiting HCV evolution (n = 34) and persistent viremia (n = 31) [median (interquartile range) signal/cut-off ratio (s/co) 78.7 (60.7-93.8) vs. 93.9 (67.8-111.9), p = 0.26]. During 12-months follow-up, patients with acute spontaneous resolving HCV infection showed significantly lower serial antibody response in comparison to individuals progressing to chronic infection [median (interquartile range) s/co 62.7 (35.2-85.0) vs. 98.4 (70.4-127.4), p < 0.0001]. In addition, patients with self-limiting HCV evolution exhibited an expeditious, sharp decline of serial antibody values after SVC in comparison to those measured before SVC [median (interquartile range) s/co 56.0 (25.4-79.3) vs. 79.4 (66.3-103.0), p < 0.0001].

Conclusion

Our findings indicate a rapid short-term decline of antibody values in patients with acute spontaneous resolving HCV infection.
Appendix
Available only for authorised users
Literature
1.
go back to reference Gerlach JT, Diepolder HM, Zachoval R, Gruener NH, Jung MC, Ulsenheimer A, Schraut WW, Schirren CA, Waechtler M, Backmund M, Pape GR: Acute hepatitis C: high rate of both spontaneous and treatment-induced viral clearance. Gastroenterology. 2003, 125: 80-88. 10.1016/S0016-5085(03)00668-1.CrossRefPubMed Gerlach JT, Diepolder HM, Zachoval R, Gruener NH, Jung MC, Ulsenheimer A, Schraut WW, Schirren CA, Waechtler M, Backmund M, Pape GR: Acute hepatitis C: high rate of both spontaneous and treatment-induced viral clearance. Gastroenterology. 2003, 125: 80-88. 10.1016/S0016-5085(03)00668-1.CrossRefPubMed
2.
go back to reference Corey KE, Ross AS, Wurcel A, Schulze Zur Wiesch J, Kim AY, Lauer GM, Chung RT: Outcomes and treatment of acute hepatitis C virus infection in a United States population. Clin Gastroenterol Hepatol. 2006, 4: 1278-1282. 10.1016/j.cgh.2006.06.026.CrossRefPubMedPubMedCentral Corey KE, Ross AS, Wurcel A, Schulze Zur Wiesch J, Kim AY, Lauer GM, Chung RT: Outcomes and treatment of acute hepatitis C virus infection in a United States population. Clin Gastroenterol Hepatol. 2006, 4: 1278-1282. 10.1016/j.cgh.2006.06.026.CrossRefPubMedPubMedCentral
3.
go back to reference The Global Burden of Hepatitis C Working Group: Global burden of disease (GBD) for hepatitis C. J Clin Pharmacol. 2004, 44: 20-29. 10.1177/0091270003258669.CrossRef The Global Burden of Hepatitis C Working Group: Global burden of disease (GBD) for hepatitis C. J Clin Pharmacol. 2004, 44: 20-29. 10.1177/0091270003258669.CrossRef
4.
go back to reference Maheshwari A, Ray S, Thuluvath PJ: Acute hepatitis C. Lancet. 2008, 372: 321-332. 10.1016/S0140-6736(08)61116-2.CrossRefPubMed Maheshwari A, Ray S, Thuluvath PJ: Acute hepatitis C. Lancet. 2008, 372: 321-332. 10.1016/S0140-6736(08)61116-2.CrossRefPubMed
5.
go back to reference Thomas DL, Seeff LB: Natural history of hepatitis C. Clin Liver Dis. 2005, 9: 383-398. 10.1016/j.cld.2005.05.003.CrossRefPubMed Thomas DL, Seeff LB: Natural history of hepatitis C. Clin Liver Dis. 2005, 9: 383-398. 10.1016/j.cld.2005.05.003.CrossRefPubMed
6.
go back to reference Micallef JM, Kaldor JM, Dore GJ: Spontaneous viral clearance following acute hepatitis C infection: A systematic review of longitudinal studies. J Viral Hepat. 2006, 13: 34-41. 10.1111/j.1365-2893.2005.00651.x.CrossRefPubMed Micallef JM, Kaldor JM, Dore GJ: Spontaneous viral clearance following acute hepatitis C infection: A systematic review of longitudinal studies. J Viral Hepat. 2006, 13: 34-41. 10.1111/j.1365-2893.2005.00651.x.CrossRefPubMed
7.
go back to reference Hofer H, Watkins-Riedel T, Janata O, Penner E, Holzmann H, Steindl-Munda P, Gangl A, Ferenci P: Spontaneous viral clearance in patients with acute hepatitis C can be predicted by repeated measurements of serum viral load. Hepatology. 2003, 37: 60-64. 10.1053/jhep.2003.50019.CrossRefPubMed Hofer H, Watkins-Riedel T, Janata O, Penner E, Holzmann H, Steindl-Munda P, Gangl A, Ferenci P: Spontaneous viral clearance in patients with acute hepatitis C can be predicted by repeated measurements of serum viral load. Hepatology. 2003, 37: 60-64. 10.1053/jhep.2003.50019.CrossRefPubMed
8.
go back to reference Jaeckel E, Cornberg M, Wedemeyer H, Santantonio T, Mayer J, Zankel M, Pastore G, Dietrich M, Trautwein C, Manns MP, German Acute Hepatitis C Therapy Group: Treatment of acute hepatitis C with interferon alfa-2b. N Engl J Med. 2001, 345: 1452-1457. 10.1056/NEJMoa011232.CrossRefPubMed Jaeckel E, Cornberg M, Wedemeyer H, Santantonio T, Mayer J, Zankel M, Pastore G, Dietrich M, Trautwein C, Manns MP, German Acute Hepatitis C Therapy Group: Treatment of acute hepatitis C with interferon alfa-2b. N Engl J Med. 2001, 345: 1452-1457. 10.1056/NEJMoa011232.CrossRefPubMed
9.
10.
go back to reference Wang CC, Krantz E, Klarquist J, Krows M, McBride L, Scott EP, Shaw-Stiffel T, Weston SJ, Thiede H, Wald A, Rosen HR: Acute hepatitis C in a contemporary US cohort: Modes of acquisition and factors influencing viral clearance. J Infect Dis. 2007, 196: 1474-1482. 10.1086/522608.CrossRefPubMed Wang CC, Krantz E, Klarquist J, Krows M, McBride L, Scott EP, Shaw-Stiffel T, Weston SJ, Thiede H, Wald A, Rosen HR: Acute hepatitis C in a contemporary US cohort: Modes of acquisition and factors influencing viral clearance. J Infect Dis. 2007, 196: 1474-1482. 10.1086/522608.CrossRefPubMed
11.
go back to reference Sharaf Eldin N, Ismail S, Mansour H, Rekacewicz C, El-Houssinie M, El-Kafrawy S, El Aidi S, Abdel-Hamid M, Esmat G, Pol S, Fontanet A, Mohamed MK: Symptomatic acute hepatitis C in Egypt: diagnosis, spontaneous viral clearance, and delayed treatment with 12 weeks of pegylated interferon alfa-2a. PLoS One. 2008, 3 (12): e4085-10.1371/journal.pone.0004085.CrossRefPubMedPubMedCentral Sharaf Eldin N, Ismail S, Mansour H, Rekacewicz C, El-Houssinie M, El-Kafrawy S, El Aidi S, Abdel-Hamid M, Esmat G, Pol S, Fontanet A, Mohamed MK: Symptomatic acute hepatitis C in Egypt: diagnosis, spontaneous viral clearance, and delayed treatment with 12 weeks of pegylated interferon alfa-2a. PLoS One. 2008, 3 (12): e4085-10.1371/journal.pone.0004085.CrossRefPubMedPubMedCentral
12.
go back to reference Cox AL, Page K, Bruneau J, Shoukry NH, Lauer GM, Kim AY, Rosen HR, Radziewicz H, Grakoui A, Fierer DS, Branch AD, Kaplan DE, Chang KM: Rare birds in North America: acute hepatitis C cohorts. Gastroenterology. 2009, 136: 26-31. 10.1053/j.gastro.2008.11.049.CrossRefPubMed Cox AL, Page K, Bruneau J, Shoukry NH, Lauer GM, Kim AY, Rosen HR, Radziewicz H, Grakoui A, Fierer DS, Branch AD, Kaplan DE, Chang KM: Rare birds in North America: acute hepatitis C cohorts. Gastroenterology. 2009, 136: 26-31. 10.1053/j.gastro.2008.11.049.CrossRefPubMed
13.
go back to reference Takaki A, Wiese M, Maertens G, Depla E, Seifert U, Liebetrau A, Miller JL, Manns MP, Rehermann B: Cellular immune responses persist and humoral responses decrease two decades after recovery from a single-source outbreak of hepatitis C. Nat Med. 2000, 6: 578-582. 10.1038/75063.CrossRefPubMed Takaki A, Wiese M, Maertens G, Depla E, Seifert U, Liebetrau A, Miller JL, Manns MP, Rehermann B: Cellular immune responses persist and humoral responses decrease two decades after recovery from a single-source outbreak of hepatitis C. Nat Med. 2000, 6: 578-582. 10.1038/75063.CrossRefPubMed
14.
go back to reference Orland JR, Wright TL, Cooper S: Acute hepatitis C. Hepatology. 2001, 33: 321-327. 10.1053/jhep.2001.22112.CrossRefPubMed Orland JR, Wright TL, Cooper S: Acute hepatitis C. Hepatology. 2001, 33: 321-327. 10.1053/jhep.2001.22112.CrossRefPubMed
15.
go back to reference Netski DM, Mosbruger T, Depla E, Maertens G, Ray SC, Hamilton RG, Roundtree S, Thomas DL, McKeating J, Cox A: Humoral immune response in acute hepatitis C virus infection. Clin Infect Dis. 2005, 41: 667-675. 10.1086/432478.CrossRefPubMed Netski DM, Mosbruger T, Depla E, Maertens G, Ray SC, Hamilton RG, Roundtree S, Thomas DL, McKeating J, Cox A: Humoral immune response in acute hepatitis C virus infection. Clin Infect Dis. 2005, 41: 667-675. 10.1086/432478.CrossRefPubMed
16.
go back to reference Chen M, Sällberg M, Sönnerborg A, Weiland O, Mattsson L, Jin L, Birkett A, Peterson D, Milich DR: Limited humoral immunity in hepatitis C virus infection. Gastroenterology. 1999, 116: 135-143. 10.1016/S0016-5085(99)70237-4.CrossRefPubMed Chen M, Sällberg M, Sönnerborg A, Weiland O, Mattsson L, Jin L, Birkett A, Peterson D, Milich DR: Limited humoral immunity in hepatitis C virus infection. Gastroenterology. 1999, 116: 135-143. 10.1016/S0016-5085(99)70237-4.CrossRefPubMed
17.
go back to reference Heller T, Rehermann B: Acute hepatitis C: a multifaceted disease. Semin Liver Dis. 2005, 25: 7-17. 10.1055/s-2005-864778.CrossRefPubMed Heller T, Rehermann B: Acute hepatitis C: a multifaceted disease. Semin Liver Dis. 2005, 25: 7-17. 10.1055/s-2005-864778.CrossRefPubMed
18.
go back to reference Logvinoff C, Major ME, Oldach D, Heyward S, Talal A, Balfe P, Feinstone SM, Alter H, Rice CM, McKeating JA: Neutralizing antibody response during acute and chronic hepatitis C virus infection. Proc Natl Acad Sci USA. 2004, 101: 10149-10154. 10.1073/pnas.0403519101.CrossRefPubMedPubMedCentral Logvinoff C, Major ME, Oldach D, Heyward S, Talal A, Balfe P, Feinstone SM, Alter H, Rice CM, McKeating JA: Neutralizing antibody response during acute and chronic hepatitis C virus infection. Proc Natl Acad Sci USA. 2004, 101: 10149-10154. 10.1073/pnas.0403519101.CrossRefPubMedPubMedCentral
19.
go back to reference Nikolaeva LI, Blokhina NP, Tsurikova NN, Voronkova NV, Miminoshvili MI, Braginsky DM, Yastrebova ON, Booynitskaya OB, Isaeva OV, Michailov MI, Archakov AI: Virus-specific antibody titers in different phases of hepatitis C virus infection. J Viral Hepat. 2002, 9: 429-437. 10.1046/j.1365-2893.2002.00369.x.CrossRefPubMed Nikolaeva LI, Blokhina NP, Tsurikova NN, Voronkova NV, Miminoshvili MI, Braginsky DM, Yastrebova ON, Booynitskaya OB, Isaeva OV, Michailov MI, Archakov AI: Virus-specific antibody titers in different phases of hepatitis C virus infection. J Viral Hepat. 2002, 9: 429-437. 10.1046/j.1365-2893.2002.00369.x.CrossRefPubMed
20.
go back to reference Lewis-Ximenez LL, Lauer GM, Schulze Zur Wiesch J, de Sousa PS, Ginuino CF, Paranhos-Baccalá G, Ulmer H, Pfeiffer KP, Goebel G, Pereira JL, Mendes de Oliveira J, Yoshida CF, Lampe E, Velloso CE, Alves Pinto M, Coelho HS, Almeida AJ, Fernandes CA, Kim AY, Strasak AM: Prospective Follow-Up of Patients with Acute Hepatitis C Virus Infection in Brazil. Clin Infect Dis. 2010, 50: 1222-1230. 10.1086/651599.CrossRefPubMed Lewis-Ximenez LL, Lauer GM, Schulze Zur Wiesch J, de Sousa PS, Ginuino CF, Paranhos-Baccalá G, Ulmer H, Pfeiffer KP, Goebel G, Pereira JL, Mendes de Oliveira J, Yoshida CF, Lampe E, Velloso CE, Alves Pinto M, Coelho HS, Almeida AJ, Fernandes CA, Kim AY, Strasak AM: Prospective Follow-Up of Patients with Acute Hepatitis C Virus Infection in Brazil. Clin Infect Dis. 2010, 50: 1222-1230. 10.1086/651599.CrossRefPubMed
21.
go back to reference Amin J, Law MG, Micallef J, Jauncey M, Van Beek I, Kaldor JM, Dore GJ: Potential biases in estimates of hepatitis C RNA clearance in newly acquired hepatitis C infection among a cohort of injecting drug users. Epidemiol Infect. 2007, 135: 144-150. 10.1017/S0950268806006388.CrossRefPubMed Amin J, Law MG, Micallef J, Jauncey M, Van Beek I, Kaldor JM, Dore GJ: Potential biases in estimates of hepatitis C RNA clearance in newly acquired hepatitis C infection among a cohort of injecting drug users. Epidemiol Infect. 2007, 135: 144-150. 10.1017/S0950268806006388.CrossRefPubMed
22.
go back to reference Cox AL, Netski DM, Mosbruger T, Sherman SG, Strathdee S, Ompad D, Vlahov D, Chien D, Shyamala V, Ray SC, Thomas DL: Prospective evaluation of community-acquired acute-phase hepatitis C virus infection. Clin Infect Dis. 2005, 40: 951-958. 10.1086/428578.CrossRefPubMed Cox AL, Netski DM, Mosbruger T, Sherman SG, Strathdee S, Ompad D, Vlahov D, Chien D, Shyamala V, Ray SC, Thomas DL: Prospective evaluation of community-acquired acute-phase hepatitis C virus infection. Clin Infect Dis. 2005, 40: 951-958. 10.1086/428578.CrossRefPubMed
23.
go back to reference McGovern BH, Birch CE, Bowen MJ, Reyor LL, Nagami EH, Chung RT, Kim AY: Improving the diagnosis of acute hepatitis C virus infection with expanded viral load criteria. Clin Infect Dis. 2009, 49: 1051-1060. 10.1086/605561.CrossRefPubMedPubMedCentral McGovern BH, Birch CE, Bowen MJ, Reyor LL, Nagami EH, Chung RT, Kim AY: Improving the diagnosis of acute hepatitis C virus infection with expanded viral load criteria. Clin Infect Dis. 2009, 49: 1051-1060. 10.1086/605561.CrossRefPubMedPubMedCentral
24.
go back to reference Messick K, Sanders JC, Goedert JJ, Eyster ME: Hepatitis C viral clearance and antibody reactivity patterns in persons with haemophilia and other congenital bleeding disorders. Haemophilia. 2001, 7: 568-574. 10.1046/j.1365-2516.2001.00559.x.CrossRefPubMed Messick K, Sanders JC, Goedert JJ, Eyster ME: Hepatitis C viral clearance and antibody reactivity patterns in persons with haemophilia and other congenital bleeding disorders. Haemophilia. 2001, 7: 568-574. 10.1046/j.1365-2516.2001.00559.x.CrossRefPubMed
25.
go back to reference Lu SN, Tung HD, Chen TM, Lee CM, Wang JH, Hung CH, Chen CH, Changchien CS: Is it possible to diagnose acute hepatitis C virus (HCV) infection by a rising anti-HCV titre rather than by seroconversion?. J Viral Hepat. 2004, 11: 563-570. 10.1111/j.1365-2893.2004.00533.x.CrossRefPubMed Lu SN, Tung HD, Chen TM, Lee CM, Wang JH, Hung CH, Chen CH, Changchien CS: Is it possible to diagnose acute hepatitis C virus (HCV) infection by a rising anti-HCV titre rather than by seroconversion?. J Viral Hepat. 2004, 11: 563-570. 10.1111/j.1365-2893.2004.00533.x.CrossRefPubMed
26.
go back to reference Lefrère JJ, Guiramand S, Lefrère F, Mariotti M, Aumont P, Lerable J, Petit JC, Girot R, Morand-Joubert L: Full or partial seroreversion in patients infected by hepatitis C virus. J Infect Dis. 1997, 175: 316-322.CrossRefPubMed Lefrère JJ, Guiramand S, Lefrère F, Mariotti M, Aumont P, Lerable J, Petit JC, Girot R, Morand-Joubert L: Full or partial seroreversion in patients infected by hepatitis C virus. J Infect Dis. 1997, 175: 316-322.CrossRefPubMed
27.
go back to reference Shata MT, Tricoche N, Perkus M, Tom D, Brotman B, McCormack P, Pfahler W, Lee DH, Tobler LH, Busch M, Prince AM: Exposure to low infective doses of HCV induces cellular immune responses without consistently detectable viremia or seroconversion in chimpanzees. Virology. 2003, 314: 601-616. 10.1016/S0042-6822(03)00461-6.CrossRefPubMedPubMedCentral Shata MT, Tricoche N, Perkus M, Tom D, Brotman B, McCormack P, Pfahler W, Lee DH, Tobler LH, Busch M, Prince AM: Exposure to low infective doses of HCV induces cellular immune responses without consistently detectable viremia or seroconversion in chimpanzees. Virology. 2003, 314: 601-616. 10.1016/S0042-6822(03)00461-6.CrossRefPubMedPubMedCentral
28.
go back to reference Bossi V, Galli C: Quantitative signal of anti-HCV by an automated assay predicts viremia in a population at high prevalence of hepatitis C virus infection. J Clin Virol. 2004, 30: 45-49. 10.1016/j.jcv.2003.08.007.CrossRefPubMed Bossi V, Galli C: Quantitative signal of anti-HCV by an automated assay predicts viremia in a population at high prevalence of hepatitis C virus infection. J Clin Virol. 2004, 30: 45-49. 10.1016/j.jcv.2003.08.007.CrossRefPubMed
Metadata
Title
Antibody dynamics and spontaneous viral clearance in patients with acute hepatitis C infection in Rio de Janeiro, Brazil
Authors
Alexander M Strasak
Arthur Y Kim
Georg M Lauer
Paulo S de Sousa
Cleber F Ginuino
Carlos A Fernandes
Carlos E Velloso
Adilson J de Almeida
Jaqueline M de Oliveira
Clara F Yoshida
Julian Schulze zur Wiesch
Gláucia Paranhos-Baccalá
Stefan Lang
Larry J Brant
Hanno Ulmer
Susanne Strohmaier
Lalit Kaltenbach
Elisabeth Lampe
Lia L Lewis-Ximenez
Publication date
01-12-2011
Publisher
BioMed Central
Published in
BMC Infectious Diseases / Issue 1/2011
Electronic ISSN: 1471-2334
DOI
https://doi.org/10.1186/1471-2334-11-15

Other articles of this Issue 1/2011

BMC Infectious Diseases 1/2011 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.